Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

In this double-blind trial, patients with chronic kidney disease and type 2 diabetes were randomly assigned to receive the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone or placebo. Treatment with finerenone resulted in lower risks of chronic kidney disease outcomes and car...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-12, Vol.383 (23), p.2219-2229
Hauptverfasser:	Bakris, George L, Agarwal, Rajiv, Anker, Stefan D, Pitt, Bertram, Ruilope, Luis M, Rossing, Peter, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Joseph, Amer, Filippatos, Gerasimos
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Albumin Albuminuria - drug therapy Angiotensin Cerebral infarction Clinical medicine Clinical trials Collaboration Creatinine Creatinine - urine Design Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - complications Diabetic Nephropathies Diabetic retinopathy Double-Blind Method Epidermal growth factor receptors Female Glomerular filtration rate Glomerular Filtration Rate - drug effects Heart diseases Humans Hyperkalemia Hyperkalemia - chemically induced Hyperkalemia - epidemiology Kidney diseases Laboratories Long-term effects Male Medicin och hälsovetenskap Myocardial infarction Naphthyridines - therapeutic use Patient safety Renal failure Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy Renin Retinopathy Statistical analysis Treatment Outcome Violations
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this double-blind trial, patients with chronic kidney disease and type 2 diabetes were randomly assigned to receive the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone or placebo. Treatment with finerenone resulted in lower risks of chronic kidney disease outcomes and cardiovascular outcomes than placebo.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2025845